SUBSCRIBERS
Shire to buy rare-disease drugmaker NPS Pharmaceuticals for US$5.2b
Deal comes before NPS learns whether its Natpara medicine to treat hypoparathyroidism wins approval from the US FDA
Published Mon, Jan 12, 2015 · 09:50 PM
London
SHIRE plc, the drugmaker seeking to boost growth after its proposed sale to AbbVie Inc collapsed, agreed to buy NPS Pharmaceuticals Inc for about US$5.2 billion to add medicines used to treat rare diseases.
Shire will pay US$46 a share in cash, the Dublin-based company said on Sunday in a statement. That's a 9.8 per cent premium to NPS's closing price on Jan 9 and more than 50 per cent higher than its close on Dec 16, before news broke of Shire's interest. The deal has been approved by both companies' boards.
Share with us your feedback on BT's products and services
